Flow Cytometry Analysis in Breast Implant-Associated Anaplastic Large Cell Lymphoma: Three Case Reports.

Breast Implant-Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare T-cell non-Hodgkin lymphoma associated with breast prosthetic implants and represents a diagnostic challenge. The National Comprehensive Cancer Network (NCCN) guidelines, updated in 2024, recommend for diagnosis an integrated work-up that should include cell morphology, CD30 immunohistochemistry (IHC), and flow cytometry (FCM). CD30 IHC, although the test of choice for BIA-ALCL diagnosis, is not pathognomonic, and this supports the recommendation to apply a multidisciplinary approach.

Circulating haematopoietic stem cells and long-term outcomes of COVID-19.

Background And Aims: An acute depletion of circulating haematopoietic stem/progenitor cells (HSPCs) occurs during COVID-19, especially among patients with a poorer disease course. We herein examined whether HSPCs levels at hospital admission for COVID-19 predict 1-year mortality and the long-COVID syndrome.

Materials And Methods: Patients hospitalized for COVID-19 in an infectious disease ward were consecutively enrolled.

T Cell Senescence by Extensive Phenotyping: An Emerging Feature of COVID-19 Severity.

Objective: To identify the potential prognostic value of lymphocyte subsets in COVID-19 patients, where lymphopenia is a common finding.

Methods: In 353 COVID-19 inpatients and 40 controls T cell subsets with markers of senescence and exhaustion were studied by flow cytometry.

Results: In severe illness, total lymphocytes B, NK, and all T subsets were dampened.

Neonatal lymphocyte subpopulations analysis and maternal preterm premature rupture of membranes: a pilot study.

Objectives: Preterm premature rupture of membranes (pPROM) causes preterm delivery, and increases maternal T-cell response against the fetus. Fetal inflammatory response prompts maturation of the newborn's immunocompetent cells, and could be associated with unfavorable neonatal outcome. The aims were (1) to examine the effects of pPROM on the newborn's and mother's immune system and (2) to assess the predictive value of immune system changes in neonatal morbidity.